Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023 · see citing works

Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001

Mokdad, A. H., Ford, E. S., Bowman, B. A., Dietz, W. H., Vinicor, F., Bales, V. S., & Marks, J. S. (2003) · JAMA · doi:10.1001/jama.289.1.76 · Cited by 5,866 · see citing works

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · see citing works

Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346 · see citing works

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study

Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · see citing works

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats.

Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209 · see citing works

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · see citing works

Pharmacologic Therapy for Type 2 Diabetes Mellitus

DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173 · see citing works

Diabetes trends in the U.S.: 1990-1998.

Mokdad, A. H., Ford, E. S., Bowman, B. A., Nelson, D. E., Engelgau, M. M., Vinicor, F., & Marks, J. S. (2000) · Diabetes Care · doi:10.2337/diacare.23.9.1278 · Cited by 1,042 · see citing works

World Medical Association Declaration of Helsinki: Recommendations Guiding Physicians in Biomedical Research Involving Human Subjects

(1997) · JAMA · doi:10.1001/jama.1997.03540350075038 · Cited by 1,023 · see citing works

Glycemic Control From 1988 to 2000 Among U.S. Adults Diagnosed With Type 2 Diabetes

Koro, C. E., Bowlin, S. J., Bourgeois, N., & Fedder, D. O. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.17 · Cited by 648 · see citing works

The Epidemic of Obesity

Stein, C. J., & Colditz, G. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0288 · Cited by 635 · see citing works

Intentional weight loss and mortality among overweight individuals with diabetes.

Williamson, D. F., Thompson, T. J., Thun, M. J., Flanders, D. W., Pamuk, E. R., & Byers, T. (2000) · Diabetes Care · doi:10.2337/diacare.23.10.1499 · Cited by 558 · see citing works

Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 Diabetes

Kolterman, O., Buse, J. B., Fineman, M. S., Gaines, E., Heintz, S., Bicsak, T. A., Taylor, K., Kim, D. S., Aisporna, M., Wang, Y., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021545 · Cited by 549 · see citing works

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers

Edwards, C. M. B., Stanley, S. A., Davis, R. P., Brynes, A. E., Frost, G. S., Seal, L., Ghatei, M. A., & Bloom, S. R. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.1.e155 · Cited by 464 · see citing works

Relationships of Upper Gastrointestinal Motor and Sensory Function With Glycemic Control

Rayner, C. K., Samsom, M., Jones, K. L., & Horowitz, M. (2001) · Diabetes Care · doi:10.2337/diacare.24.2.371 · Cited by 459 · see citing works

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

Nielsen, L. L., Young, A. A., & Parkes, D. G. (2003) · Regulatory Peptides · doi:10.1016/j.regpep.2003.10.028 · Cited by 455 · see citing works

Importance of Weight Management in Type 2 Diabetes: Review with Meta-analysis of Clinical Studies

Anderson, J. W., Kendall, C. W. C., & Jenkins, D. J. A. (2003) · Journal of the American College of Nutrition · doi:10.1080/07315724.2003.10719316 · Cited by 448 · see citing works

Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).

Young, A. A., Gedulin, B. R., Bhavsar, S., Bodkin, N., Jodka, C., Hansen, B., & Denaro, M. (1999) · Diabetes · doi:10.2337/diabetes.48.5.1026 · Cited by 440 · see citing works

Sulfonylureas in NIDDM

Groop, L. C. (1992) · Diabetes Care · doi:10.2337/diacare.15.6.737 · Cited by 408 · see citing works

Glucagon-Like Peptide-1 and Exendin-4 Stimulate β-Cell Neogenesis in Streptozotocin-Treated Newborn Rats Resulting in Persistently Improved Glucose Homeostasis at Adult Age

Tourrel‐Cuzin, C., Bailbé, D., Meile, M.-J., Kergoat, M., & Portha, B. (2001) · Diabetes · doi:10.2337/diabetes.50.7.1562 · Cited by 362 · see citing works

Obesity and type 2 diabetes

Maggio, C. A., & Pi-Sunyer, X. (2003) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(03)00071-9 · Cited by 352 · see citing works

Exendin-4 Decelerates Food Intake, Weight Gain, and Fat Deposition in Zucker Rats

Szayna, M., Doyle, M. E., Betkey, J. A., Holloway, H. W., Spencer, R. G. S., Greig, N. H., & Egan, J. M. (2000) · Endocrinology · doi:10.1210/endo.141.6.7490 · Cited by 303 · see citing works

Combination therapies with insulin in type 2 diabetes

Yki-Järvinen, H. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.758 · Cited by 300 · see citing works

Persistent Improvement of Type 2 Diabetes in the Goto-Kakizaki Rat Model by Expansion of the β-Cell Mass During the Prediabetic Period With Glucagon-Like Peptide-1 or Exendin-4

Tourrel‐Cuzin, C., Bailbé, D., Lacorne, M., Meile, M.-J., Kergoat, M., & Portha, B. (2002) · Diabetes · doi:10.2337/diabetes.51.5.1443 · Cited by 285 · see citing works

The Insulinotropic Effect of Acute Exendin-4 Administered to Humans: Comparison of Nondiabetic State to Type 2 Diabetes

Egan, J. M., Clocquet, A. R., & Elahi, D. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8337 · Cited by 247 · see citing works

Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro

Parkes, D. G., Pittner, R. A., Jodka, C. M., Smith, P., & Young, A. J. (2001) · Metabolism · doi:10.1053/meta.2001.22519 · Cited by 241 · see citing works

Exenatide (Exendin-4) Improves Insulin Sensitivity and β-Cell Mass in Insulin-Resistant Obesefa/faZucker Rats Independent of Glycemia and Body Weight

Gedulin, B. R., Nikoulina, S. E., Smith, P. A., Gedulin, G., Nielsen, L. L., Baron, A., Parkes, D. G., & Young, A. A. (2004) · Endocrinology · doi:10.1210/en.2004-1349 · Cited by 241 · see citing works

Dose-Dependent Effects of Glyburide on Insulin Secretion and Glucose Uptake in Humans

Groop, L., Barzilai, N., Ratheiser, K., Luzi, L., Wahlin‐Boll, E., Melander, A., & DeFronzo, R. A. (1991) · Diabetes Care · doi:10.2337/diacare.14.8.724 · Cited by 74 · see citing works

Impaired effect of sulfonylurea following increased dosage

Wahlin‐Boll, E., Sartor, G., Melander, A., & Scherstén, B. (1982) · European Journal of Clinical Pharmacology · doi:10.1007/bf00606420 · Cited by 54 · see citing works

Attenuating CV risk factors in patients with diabetes: clinical evidence to clinical practice

Garber, A. J. (2002) · Diabetes Obesity and Metabolism · doi:10.1046/j.1462-8902.2001.00038.x · Cited by 50 · see citing works

The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · see citing works

The Physiology of Glucagon-like Peptide 1

Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · see citing works

Mechanisms of diabetes mellitus-induced bone fragility

On behalf of the IOF Bone and Diabetes Working Group, Napoli, N., Chandran, M., Pierroz, D. D., Abrahamsen, B., Schwartz, A. V., & Ferrari, S. L. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.153 · Cited by 1,107 · see citing works

β-Cell Failure in Diabetes and Preservation by Clinical Treatment

WAJCHENBERG, B. L. (2007) · Endocrine Reviews · doi:10.1210/10.1210/er.2006-0038 · Cited by 716 · see citing works

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699 · see citing works

Mechanisms of action of glucagon-like peptide 1 in the pancreas

Doyle, M. E., & Egan, J. M. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.11.007 · Cited by 679 · see citing works

Anti-Obesity Drugs: A Review about Their Effects and Safety

Kang, J. G., & Park, C. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.1.13 · Cited by 592 · see citing works

Cardiovascular Biology of the Incretin System

Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 527 · see citing works

Obesity‐Related Hypertension: Pathogenesis, Cardiovascular Risk, and Treatment: A Position Paper of <i>The Obesity Society</i> and the <i>American Society of Hypertension</i>

Landsberg, L., Aronne, L. J., Beilin, L. J., Burke, V., Igel, L. I., Lloyd‐Jones, D., & Sowers, J. (2013) · The Journal of Clinical Hypertension · doi:10.1111/jch.12049 · Cited by 528 · see citing works

GLP-1 Neurons in the Nucleus of the Solitary Tract Project Directly to the Ventral Tegmental Area and Nucleus Accumbens to Control for Food Intake

Alhadeff, A. L., Rupprecht, L. E., & Hayes, M. R. (2012) · Endocrinology · doi:10.1210/en.2011-1443 · Cited by 515 · see citing works

The incretin system and its role in type 2 diabetes mellitus

Holst, J. J., Vilsboll, T., & Deacon, C. F. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.08.012 · Cited by 516 · see citing works

Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes

Kim, D. S., MacConell, L., Zhuang, D., Kothare, P. A., TRAUTMANN, M. E., Fineman, M. S., & Taylor, K. (2007) · Diabetes Care · doi:10.2337/dc06-2375 · Cited by 447 · see citing works

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study

Nauck, M. A., Duran, S., Kim, D., Johns, D., Northrup, J., Festa, A., Brodows, R. G., & TRAUTMANN, M. E. (2006) · Diabetologia · doi:10.1007/s00125-006-0510-2 · Cited by 430 · see citing works

The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes

Zinman, B., Hoogwerf, B. J., García, S. D., Milton, D. R., Giaconia, J. M., Kim, D. D. H., TRAUTMANN, M. E., & Brodows, R. G. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-7-200704030-00003 · Cited by 422 · see citing works

A Review of Diabetes Treatment Adherence and the Association with Clinical and Economic Outcomes

Asche, C., LaFleur, J., & Conner, C. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.01.019 · Cited by 420 · see citing works

Cardiovascular Actions of Incretin-Based Therapies

Ussher, J. R., & Drucker, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.301958 · Cited by 358 · see citing works

Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4

Kanoski, S. E., Fortin, S. M., Arnold, M., Grill, H. J., & Hayes, M. R. (2011) · Endocrinology · doi:10.1210/en.2011-0174 · Cited by 347 · see citing works

Metformin therapy and clinical uses

Scarpello, J. H., & Howlett, H. C. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.027 · Cited by 318 · see citing works

The Evidence for Medical Nutrition Therapy for Type 1 and Type 2 Diabetes in Adults

Franz, M. J., Powers, M. A., Leontos, C., Holzmeister, L. A., Kulkarni, K. D., Monk, A. M., Wedel, N., & Gradwell, E. (2010) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2010.09.014 · Cited by 308 · see citing works

Obesity‐related hypertension: Pathogenesis, cardiovascular risk, and treatment—A position paper of the The Obesity Society and the American Society of Hypertension

Landsberg, L., Aronne, L. J., Beilin, L. J., Burke, V., Igel, L. I., Lloyd‐Jones, D. M., & Sowers, J. R. (2012) · Obesity · doi:10.1002/oby.20181 · Cited by 286 · see citing works

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials

Buse, J. B., Klonoff, D. C., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Maggs, D. G., & Wintle, M. E. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.01.015 · Cited by 279 · see citing works

The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide

Kanoski, S. E., Rupprecht, L. E., Fortin, S. M., De Jonghe, B. C., & Hayes, M. R. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.12.022 · Cited by 273 · see citing works

Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes

Ferrannini, E., & DeFronzo, R. A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv239 · Cited by 256 · see citing works

Glucagon-like peptide analogues for type 2 diabetes mellitus

Shyangdan, D. S., Royle, P., Clar, C., Sharma, P., Waugh, N., & Snaith, A. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006423.pub2 · Cited by 246 · see citing works

Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness

Madsen, K., Knudsen, L. B., Agersoe, H., Nielsen, P. F., Thøgersen, H., Wilken, M., & Johansen, N. L. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070861j · Cited by 244 · see citing works

Pharmacotherapies for Obesity: Past, Current, and Future Therapies

Ioannides‐Demos, L. L., Piccenna, L. G., & McNeil, J. J. (2010) · Journal of Obesity · doi:10.1155/2011/179674 · Cited by 244 · see citing works

Blood pressure‐lowering effects of <scp>GLP</scp> ‐1 receptor agonists exenatide and liraglutide: a meta‐analysis of clinical trials

Wang, B., Zhong, J., Lin, H., Zhao, Z., Yan, Z., He, H., Ni, Y., Liu, D., & Zhu, Z. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12085 · Cited by 225 · see citing works

Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors

Verspohl, E. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.002 · Cited by 193 · see citing works

Glycaemic control in type 2 diabetes: Targets and new therapies

Tahrani, A. A., Piya, M. K., Kennedy, A., & Barnett, A. H. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.11.001 · Cited by 189 · see citing works

Pharmacotherapy of type 2 diabetes: An update

Upadhyay, J., Pοlyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. Α., Katsiki, N., UNDERWOOD, P. C., Park, K., Seufert, J., Kang, E. S., et al. (2017) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 190 · see citing works

New Drugs for the Treatment of Diabetes

Inzucchi, S. E., & McGuire, D. K. (2008) · Circulation · doi:10.1161/circulationaha.107.735795 · Cited by 187 · see citing works

Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical Use

Kendall, D. M., Cuddihy, R. M., & Bergenstal, R. M. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.015 · Cited by 177 · see citing works

The nucleus tractus solitarius: a portal for visceral afferent signal processing, energy status assessment and integration of their combined effects on food intake

Grill, H. J., & Hayes, M. R. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.10 · Cited by 174 · see citing works

Intestinal Microbiota During Infancy and Its Implications for Obesity

Reinhardt, C., Reigstad, C. S., & Bäckhed, F. (2009) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e318183187c · Cited by 173 · see citing works

Role of the glucagon-like-peptide-1 receptor in the control of energy balance

Hayes, M. R., De Jonghe, B. C., & Kanoski, S. E. (2010) · Physiology &amp; Behavior · doi:10.1016/j.physbeh.2010.02.029 · Cited by 173 · see citing works

Manufacturing Peptides as Active Pharmaceutical Ingredients

Zompra, A. A., Galanis, A., Werbitzky, O., & Alberício, F. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.23 · Cited by 170 · see citing works

Metabolic Syndrome: From Global Epidemiology to Individualized Medicine

Batsis, J. A., Nieto-Martínez, R. E., & López-Jiménez, F. A. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100355 · Cited by 168 · see citing works

Pharmacological Treatment of the Overweight Patient

Bray, G. A., & Greenway, F. L. (2007) · Pharmacological Reviews · doi:10.1124/pr.59.2.2 · Cited by 167 · see citing works

Advances in the Treatment of Type 2 Diabetes Mellitus

Israili, Z. H. (2010) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181afbf51 · Cited by 163 · see citing works

Weight Loss, Glycemic Control, and Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort Database

Horton, E. S., Silberman, C., Davis, K. L., & Berria, R. (2010) · Diabetes Care · doi:10.2337/dc09-2062 · Cited by 156 · see citing works

Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK

Weiss, T., Yang, L., Carr, R. D., Pal, S., Sawhney, B., Boggs, R., Rajpathak, S., & Iglay, K. (2022) · BMJ Open Diabetes Research &amp; Care · doi:10.1136/bmjdrc-2021-002517 · Cited by 152 · see citing works

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

Ratner, R. E., Han, J., Nicewarner, D., Yushmanova, I., Hoogwerf, B. J., & Shen, L. Z. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-22 · Cited by 152 · see citing works

Type 2 diabetes: Where we are today: An overview of disease burden, current treatments, and treatment strategies

Campbell, R. K. (2009) · Journal of the American Pharmacists Association · doi:10.1331/japha.2009.09077 · Cited by 149 · see citing works

Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes

Dushay, J. R., Gao, C., Gopalakrishnan, G. S., Crawley, M. B., Mitten, E. K., Wilker, E. H., Mullington, J. M., & Maratos–Flier, E. (2011) · Diabetes Care · doi:10.2337/dc11-0931 · Cited by 149 · see citing works

Targeting the glucagon receptor family for diabetes and obesity therapy

Cho, Y. M., Merchant, C. E., & Kieffer, T. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.05.009 · Cited by 142 · see citing works

Glucagon‐like peptide‐1‐based therapies and cardiovascular disease: looking beyond glycaemic control

Anagnostis, P. G., Athyros, V. G., Adamidou, F., Panagiotou, A., Kita, M. D., Karagiannis, A. I., & Mikhailidis, D. P. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01345.x · Cited by 140 · see citing works

GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes

Olmo-García, M. I. D., & Merino-Torres, J. F. (2018) · Journal of Diabetes Research · doi:10.1155/2018/4020492 · Cited by 144 · see citing works

Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner

Wei, R., Ma, S., Wang, C., Ke, J., Yang, J., Li, W., Liu, Y., Hou, W., Feng, X., Wang, G., et al. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00400.2015 · Cited by 137 · see citing works

Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results

Madsbad, S. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.008 · Cited by 128 · see citing works

Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure

Liu, Q., Anderson, C. M., Broyde, A., Polizzi, C. J., Fernandez, R., Baron, A., & Parkes, D. G. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-76 · Cited by 124 · see citing works

Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus

Kovács, C. S., Seshiah, V., Merker, L., Christiansen, A. V., Roux, F., Salsali, A., Kim, G., Stella, P., Woerle, H., & Broedl, U. C. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.05.511 · Cited by 113 · see citing works

Role of Metformin for Weight Management in Patients Without Type 2 Diabetes

Desilets, A. R., Dhakal-Karki, S., & Dunican, K. C. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1k656 · Cited by 111 · see citing works

Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes

Bunck, M. C. M., Eliasson, B., Cornér, A., Heine, R. J., Shaginian, R. M., Taskinen, M., Yki‐Järvinen, H., Smith, U., & Diamant, M. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01355.x · Cited by 112 · see citing works

Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors

Pratley, R. E., & Gilbert, M. P. (2008) · The Review of Diabetic Studies · doi:10.1900/rds.2008.5.73 · Cited by 111 · see citing works

Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats

Hayes, M. R., Kanoski, S. E., Alhadeff, A. L., & Grill, H. J. (2011) · Obesity · doi:10.1038/oby.2011.50 · Cited by 110 · see citing works

Exenatide: a review from pharmacology to clinical practice

Gentilella, R., Bianchi, C., Rossi, A., & Rotella, C. M. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.01018.x · Cited by 108 · see citing works

Exenatide added to insulin therapy: A retrospective review of clinical practice over two years in an academic endocrinology outpatient setting

Yoon, N. M., Cavaghan, M. K., Brunelle, R. L., & Roach, P. J. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.07.021 · Cited by 110 · see citing works

Targeting β-Cell Function Early in the Course of Therapy for Type 2 Diabetes Mellitus

Leahy, J. L., Hirsch, I. B., PETERSON, K. A., & Schneider, D. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0668 · Cited by 108 · see citing works

Incretin-Based Therapies: Review of Current Clinical Trial Data

Peters, A. L. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.007 · Cited by 107 · see citing works

Endogenous glucagon-like peptide-1 receptor signaling in the nucleus tractus solitarius is required for food intake control

Alhadeff, A. L., Mergler, B. D., Zimmer, D. J., Turner, C. A., Reiner, D. J., Schmidt, H. D., Grill, H. J., & Hayes, M. R. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.246 · Cited by 102 · see citing works

Exenatide

Cvetkovi, R. S., & Plosker, G. L. (2007) · Drugs · doi:10.2165/00003495-200767060-00008 · Cited by 103 · see citing works

Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme

Niswender, K. D., Pi‐Sunyer, X., Buse, J. B., Jensen, K. H., Toft, A. D., Russell-Jones, D. L., & Zinman, B. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01673.x · Cited by 100 · see citing works

Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists

Uccellatore, A., Genovese, S., Dicembrini, I., Mannucci, E., & Ceriello, A. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0127-x · Cited by 99 · see citing works

Incretin physiology beyond glucagon‐like peptide 1 and glucose‐dependent insulinotropic polypeptide: cholecystokinin and gastrin peptides

Rehfeld, J. F. (2011) · Acta Physiologica · doi:10.1111/j.1748-1716.2010.02235.x · Cited by 99 · see citing works

Glucagon-like peptide-1 receptor action in the vasculature

Almutairi, M., Al Batran, R., & Ussher, J. R. (2019) · Peptides · doi:10.1016/j.peptides.2018.09.002 · Cited by 99 · see citing works

GLP‐1: physiological effects and potential therapeutic applications

Aaboe, K., Krarup, T., Madsbad, S., & Holst, J. J. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00853.x · Cited by 97 · see citing works

Exploring the Substitution of Exenatide for Insulin in Patients With Type 2 Diabetes Treated With Insulin in Combination With Oral Antidiabetes Agents

Davis, S. N., Johns, D., Maggs, D. G., Xu, H., Northrup, J., & Brodows, R. G. (2007) · Diabetes Care · doi:10.2337/dc06-2532 · Cited by 95 · see citing works

Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials

Madsbad, S., Krarup, T., Deacon, C. F., & Holst, J. J. (2008) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e328302f414 · Cited by 93 · see citing works

Incretins and Amylin: Neuroendocrine Communication Between the Gut, Pancreas, and Brain in Control of Food Intake and Blood Glucose

Hayes, M. R., Mietlicki‐Baase, E. G., Kanoski, S. E., & Jonghe, B. C. D. (2014) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071812-161201 · Cited by 90 · see citing works

Medical Antihyperglycaemic Treatment of Type 2 Diabetes Mellitus

Matthaei, S., Bierwirth, R., Fritsche, A., Gallwitz, B., Häring, H., Joost, H., Kellerer, M., Kloos, C., Kunt, T., Nauck, M. A., et al. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1239559 · Cited by 91 · see citing works

GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance

Taher, J., Baker, C. L., Cuizon, C., Masoudpour, H., Zhang, R., Farr, S., Naples, M., Bourdon, C., Pausová, Z., & Adeli, K. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.09.005 · Cited by 91 · see citing works

Exenatide efficacy and safety: a systematic review

Norris, S. L., Lee, N., Thakurta, S., & Chan, B. K. S. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02790.x · Cited by 88 · see citing works

The common hepatic branch of the vagus is not required to mediate the glycemic and food intake suppressive effects of glucagon-like-peptide-1

Hayes, M. R., Kanoski, S. E., De Jonghe, B. C., Leichner, T. M., Alhadeff, A. L., Fortin, S. M., Arnold, M., Langhans, W., & Grill, H. J. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00356.2011 · Cited by 86 · see citing works

Diabetes and obesity: therapeutic targeting and risk reduction – a complex interplay

Niswender, K. D. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01175.x · Cited by 85 · see citing works

Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk

Hoogwerf, B. J. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1978 · Cited by 87 · see citing works

Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors

Rizzo, M., Rizvi, A. A., Spinas, G. A., Rini, G. B., & Berneis, K. K. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/14728220903241633 · Cited by 83 · see citing works

DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes

Carolyn, F. D. (2007) · Frontiers in bioscience · doi:10.2741/2799 · Cited by 83 · see citing works

DPP‐IV inhibition enhances the antilipolytic action of NPY in human adipose tissue

Kos, K., Baker, A. R., Jernås, M., Harte, A. L., Clapham, J. C., O’Hare, J. P., Carlsson, L. M. S., Kumar, S., & McTernan, P. G. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00909.x · Cited by 82 · see citing works

Evolution of Exenatide as a Diabetes Therapeutic

Bhavsar, S., Mudaliar, S. R. D., & Cherrington, A. D. (2013) · Current Diabetes Reviews · doi:10.2174/1573399811309020007 · Cited by 81 · see citing works

Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes

Haering, H.-U., Merker, L., Christiansen, A. V., Roux, F., Salsali, A., Kim, G., Meinicke, T. W., Woerle, H. J., & Broedl, U. C. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.05.044 · Cited by 80 · see citing works

Anti-Diabetes and Anti-Obesity Medications: Effects on Weight in People With Diabetes

Hollander, P. A. (2007) · Diabetes Spectrum · doi:10.2337/diaspect.20.3.159 · Cited by 81 · see citing works

Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake

McKay, N. J., Kanoski, S. E., Hayes, M. R., & Daniels, D. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00472.2011 · Cited by 79 · see citing works

Exenatide

Barnett, A. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.15.2593 · Cited by 79 · see citing works

Liraglutide as Additional Treatment to Insulin in Obese Patients with Type 1 Diabetes Mellitus

Kuhadiya, N. D., Malik, R., Bellini, N. J., Patterson, J. L., Traina, A. N., Makdissi, A., & Dandona, P. (2013) · Endocrine Practice · doi:10.4158/ep13065.or · Cited by 76 · see citing works

Exploring the impact of bariatric surgery on high density lipoprotein

Aminian, A., Zelisko, A., Kirwan, J. P., Brethauer, S. A., & Schauer, P. R. (2014) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2014.07.017 · Cited by 77 · see citing works

Hindbrain leptin and glucagon-like-peptide-1 receptor signaling interact to suppress food intake in an additive manner

Zhao, S., Kanoski, S. E., Yan, J., Grill, H. J., & Hayes, M. R. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.265 · Cited by 76 · see citing works

Present and Future: Pharmacologic Treatment of Obesity

Glandt, M., & Raz, I. (2011) · Journal of Obesity · doi:10.1155/2011/636181 · Cited by 76 · see citing works

A placebo‐controlled trial of exenatide twice‐daily added to thiazolidinediones alone or in combination with metformin

Liutkus, J., Guzmán, J. R., Norwood, P. C., Pop, L., Northrup, J., Cao, D., & TRAUTMANN, M. E. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01251.x · Cited by 74 · see citing works

Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes

Blonde, L., Pencek, R., & MacConell, L. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0171-2 · Cited by 71 · see citing works

Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials

Zhong, J., Gong, Q., Goud, A., Srinivasamaharaj, S., & Rajagopalan, S. (2015) · Journal of Diabetes Research · doi:10.1155/2015/606031 · Cited by 72 · see citing works

Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: Results from an observational research

Irace, C., Luca, S. D., Shehaj, E., Carallo, C., Loprete, A., Scavelli, F. B., & Gnasso, A. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112449562 · Cited by 72 · see citing works

Incretin‐based treatment of type 2 diabetes: glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors*

Deacon, C. F. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00765.x · Cited by 70 · see citing works

The Effect of Sitagliptin Versus Glibenclamide on Arterial Stiffness, Blood Pressure, Lipids, and Inflammation in Type 2 Diabetes Mellitus Patients

Koren, S., Shemesh-Bar, L., Tirosh, A., Peleg, R. K., Berman, S., Hamad, R. A., Vinker, S., Golik, A., & Efrati, S. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0296 · Cited by 70 · see citing works

Cardiovascular Comorbidities of Type 2 Diabetes Mellitus: Defining the Potential of Glucagonlike peptide–1-Based Therapies

CHILTON, R. J., Wyatt, J., Nandish, S., OLIVEROS, R. A., & Lujan, M. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.004 · Cited by 68 · see citing works

Can Gut Hormones Control Appetite and Prevent Obesity?

Chaudhri, O. B., Wynne, K., & Bloom, S. R. (2008) · Diabetes Care · doi:10.2337/dc08-s269 · Cited by 69 · see citing works

Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes

Boye, K. S., Matza, L. S., Oglesby, A. K., Malley, K. G., Kim, S. W., Hayes, R. P., & Brodows, R. G. (2006) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-4-80 · Cited by 68 · see citing works

Anti-Inflammatory Properties of Exenatide in Human Pancreatic Islets

Cechin, S. R., Pérez-Álvarez, I., Fenjves, E., Molano, R. D., Pileggi, A., Berggren, P.-O., Ricordi, C., & Pastori, R. L. (2012) · Cell Transplantation · doi:10.3727/096368911x576027 · Cited by 67 · see citing works

The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats

Liu, Q., Adams, L. A., Broyde, A., Fernandez, R., Baron, A., & Parkes, D. G. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-32 · Cited by 66 · see citing works

Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data

Gallwitz, B. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01196.x · Cited by 63 · see citing works

Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors

Klen, J., & Dolžan, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073451 · Cited by 62 · see citing works

Long‐term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over‐weight metformin‐treated patients with type 2 diabetes mellitus

Ratner, R. E., Maggs, D., Nielsen, L. L., Stonehouse, A. H., Poon, T., Zhang, B., Bicsak, T. A., Brodows, R. G., & Kim, D. D. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00589.x · Cited by 217 · see citing works

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699 · see citing works

Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin

Riddle, M. C., Henry, R. R., Poon, T., Bei, Z., Mac, S. M., Holcombe, J. H., Kim, D. D. H., & Maggs, D. G. (2006) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.646 · Cited by 126 · see citing works

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005

Defronzo, R. A., Ratner, R. E., Ms, J. H., Kim, D. D., Fineman, M. S., & Baron, A. (2015)

Improved Glycemic Control and Reduction of Cardiometabolic Risk Factors in Subjects with Type 2 Diabetes and Metabolic Syndrome Treated with Exenatide in a Clinical Practice Setting

Bhushan, R., Elkind-Hirsch, K. E., Bhushan, M., Butler, W. J., Duncan, K., & Marrioneaux, O. (2009) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2008.0090 · Cited by 28 · see citing works